Receptors, Erythropoietin
"Receptors, Erythropoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.
| Descriptor ID |
D017467
|
| MeSH Number(s) |
D12.776.543.750.705.852.150.200 D12.776.543.750.750.400.200.340
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Erythropoietin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.705.852.150]
- Receptors, Erythropoietin [D12.776.543.750.705.852.150.200]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Colony-Stimulating Factor [D12.776.543.750.750.400.200]
- Receptors, Erythropoietin [D12.776.543.750.750.400.200.340]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Erythropoietin".
This graph shows the total number of publications written about "Receptors, Erythropoietin" by people in this website by year, and whether "Receptors, Erythropoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Erythropoietin" by people in Profiles.
-
DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016 09; 48(9):1014-23.
-
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Feb 08; 29(2):186-200.
-
Mutational profile of childhood myeloproliferative neoplasms. Leukemia. 2015 Dec; 29(12):2407-9.
-
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
-
Erythropoietin receptor mutation--a rush of blood to the head? Ann Hematol. 2015 Jul; 94(7):1229-31.
-
B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease. Mod Pathol. 2014 Mar; 27(3):382-9.
-
Hereditary myeloproliferative disorders. Haematologica. 2010 Jan; 95(1):6-8.
-
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.
-
Erythropoietin potentiates EDHF-mediated dilations in rat middle cerebral arteries. J Neurotrauma. 2008 Mar; 25(3):257-65.
-
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev. 2005 Jan; 19(1):1-13.